A technology to create and develop different products by using the biological systems, living organisms, and parts of this is called ‘Biotechnology’. A product develops rapidly by making some specific changes in the genetic material of an organism commonly called DNA.
Biotechnology industry comprises those companies that are working on the diagnostic compounds and drugs for treating specific kinds of diseases. After being passed from the costly and time-consuming process of testing, they need to get approved from the U.S. Food and Drug Administration department. It’s unclear for the investors for years that whether a product would be profitable for them or not.
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
There are small start-up companies as well as larger ones in the industry of biotechnology. In the last year, most of them worked on the vaccines for Coronavirus and that ultimately led to the raise in biotech stock. It will generate revenue in the present year for sure. Coronavirus pandemic came as a storm. Those companies that were able to sustain their products sales growth, they are surely going to be flourishing in the coming months ahead. Consequently, their stocks would be raised, ultimately benefiting the investors. The stock market is always changing. We can’t predict the future without doing thorough research in this field. Let’s find out about The 3 top most biotech stocks for 2021:
1: Bionano Genomics Inc (NASDAQ: BNGO):
In January the price of biotech stock of Bionano Genomic was $1. Its shares started to raise and it was all over the news and Twitter. They were touching the skies while there were losses as well. The company makes laboratory equipments for clinical studies and researches. Its shares are floating higher and analysts can predict the upcoming gains in its stock. BNGO shares rocked the share market by increasing up to 340% this year. Its revenue streams are a little bit unstable but it has the potential of creating a huge revenue in the coming years, raising its share value alongside.
2: Moderna (NASDAQ: MRNA):
Previously Moderna’s stocks increased 430% due to its outclass performance in research and production of coronavirus vaccine. It has developed and sold it. Currently its getting orders from around the world for the vaccine doses, that is raising its revenue. An estimated gross revenue for the year 2021 would be $15 billion. Further, it’s collaboration with the Pfizer in vaccine market is also going to cause its share to increase.
Moderna is planning to produce a vaccine for teens as well, which in return would increase its revenue. Consequently, more investors would be interested in buying MRNA’s stock.
3: Vertex Pharmaceuticals (NASDAQ: VRTX):
VRTX is working in the market for Cystic fibrosis (CF) specifically. It’s also trying to discover treatments for blood disorders including beta sickle cell disease and thalassemia. Their leadership expects to be the leaders of market for at least 10 more years in future. This made possible for Vertex to gain billions of dollars profit in the stock market. It has got $6.2 billion revenue in the earnings report of 2020.
Vertex product named Tarifta got approval from FDA in 2019. Tarifta’s production gave a boost in revenue for about $3 billion. The expectations are high for more increase in revenue during the coming years.